Business
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LYbHRS3_v8ob5T6A1Lc.4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The cohort consists of six patients, who were recruited rapidly across three premier clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.","length":770,"tagName":"p"},{"type":"text","content":"This milestone follows the recent completion of the first cohort, which demonstrated encouraging top-line safety and efficacy data, including a favorable safety profile and preliminary signals of reduced cravings and withdrawal symptoms.","length":237,"tagName":"p"},{"type":"text","content":"The swift enrollment of the second cohort—achieved in a remarkably short timeframe—highlights the strong commitment and operational excellence of the collaborating clinical centers, emphasizing their dedication to advancing innovative treatments for AUD, a condition affecting millions worldwide with limited effective options.","length":327,"tagName":"p"},{"type":"text","content":"“We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment,” stated Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “Building on the excellent results ...